Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
28
BLRX Quote, Financials, Valuation and Earnings
Last price:
$0.23
Seasonality move
:
-8.21%
Day range:
$0.22 - $0.23
52-week range:
$0.19 - $1.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.81x
P/B ratio:
2.31x
Volume:
840.5K
Avg. volume:
1.7M
1-year change:
-85.55%
Market cap:
$19.6M
Revenue:
$4.8M
EPS (TTM):
-$0.23
Analysts' Opinion
-
Consensus RatingBioLine Rx has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.75, BioLine Rx has an estimated upside of 1856.59% from its current price of $0.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.50 representing 100% downside risk from its current price of $0.23.
Fair Value
-
According to the consensus of 0 analysts, BioLine Rx has 1856.59% upside to fair value with a price target of $13.75 per share.
BLRX vs. S&P 500
-
Over the past 5 trading days, BioLine Rx has overperformed the S&P 500 by 8.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioLine Rx does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioLine Rx has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioLine Rx reported revenues of $4.9M.
Earnings Growth
-
BioLine Rx has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BioLine Rx reported earnings per share of -$0.07.
Enterprise value:
18.3M
EV / Invested capital:
0.50x
Price / LTM sales:
0.81x
EV / EBIT:
--
EV / Revenue:
0.83x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$15.1M
Return On Assets:
-34.86%
Net Income Margin (TTM):
-90.57%
Return On Equity:
-160.88%
Return On Invested Capital:
-66.36%
Operating Margin:
-108.98%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $22M | -- | $4.9M | |
| Gross Profit | -- | -- | $15.1M | -- | $4.1M | |
| Operating Income | -$27.4M | -$39.5M | -$27.8M | -$12.4M | -$5.4M | |
| EBITDA | -$21.9M | -$47.5M | -$13.3M | -$15M | -$3.4M | |
| Diluted EPS | -$0.45 | -$0.75 | -$0.23 | -$0.30 | -$0.07 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.4M | $62.8M | $57.9M | $28.8M | $37.8M | |
| Total Assets | $46M | $86.9M | $81.7M | $52.9M | $52.7M | |
| Current Liabilities | $10.5M | $10.3M | $8.1M | $14.7M | $25M | |
| Total Liabilities | $21.2M | $16M | $26.1M | $39.7M | $44.2M | |
| Total Equity | $24.8M | $70.9M | $55.5M | $13.1M | $8.5M | |
| Total Debt | $6.5M | $3.6M | $9.2M | $11.5M | $27.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.1M | -$33.3M | -$30.3M | -$9.9M | -$9.8M | |
| Cash From Investing | $4.1M | $25.7M | -$2.2M | $4.1M | $10.2M | |
| Cash From Financing | $21.3M | $2.7M | $33.5M | $3.5M | -$1.2M | |
| Free Cash Flow | -$26.2M | -$33.8M | -$30.3M | -$9.9M | -$9.8M | |
BLRX
Sector
Market Cap
$19.6M
$46.1M
Price % of 52-Week High
14.23%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-85.55%
-30.52%
Beta (5-Year)
1.394
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.21
200-day SMA
Sell
Level
$0.62
Bollinger Bands (100)
Sell
Level
0.33 - 0.67
Chaikin Money Flow
Sell
Level
-379.4M
20-day SMA
Sell
Level
$0.24
Relative Strength Index (RSI14)
Sell
Level
37.16
ADX Line
Buy
Level
13.78
Williams %R
Neutral
Level
-49.4553
50-day SMA
Sell
Level
$0.36
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
470.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.8455)
Sell
CA Score
(Annual)
Level (-4.3956)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.1232)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Stock Forecast FAQ
In the current month, BLRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLRX average analyst price target in the past 3 months is $13.75.
-
Where Will BioLine Rx Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioLine Rx share price will rise to $13.75 per share over the next 12 months.
-
What Do Analysts Say About BioLine Rx?
Analysts are divided on their view about BioLine Rx share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioLine Rx is a Sell and believe this share price will drop from its current level to $6.50.
-
What Is BioLine Rx's Price Target?
The price target for BioLine Rx over the next 1-year time period is forecast to be $13.75 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BLRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioLine Rx is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BLRX?
You can purchase shares of BioLine Rx via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioLine Rx shares.
-
What Is The BioLine Rx Share Price Today?
BioLine Rx was last trading at $0.23 per share. This represents the most recent stock quote for BioLine Rx. Yesterday, BioLine Rx closed at $0.23 per share.
-
How To Buy BioLine Rx Stock Online?
In order to purchase BioLine Rx stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
